Advert - Daiichi Sankyo – Case AUTH/3770/5/23

• Date posted
  24 October 2024
• Sanction
  Advertisement,
• Case number/s
  AUTH/3770/5/23 - Complainant v Daiichi Sankyo

For failing to state a Nustendi (bempedoic acid, ezetimibe) contraindication regarding coadministration with a statin in patients with active liver disease or unexplained persistent elevations in serum transaminases, within the tolerability section of a promotional website, which could potentially impact patient safety, Daiichi Sankyo was ruled in breach of the following clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 6.1 - Providing misleading information
Clause 6.2 - Providing misleading information that was incapable of substantiation